Lucence

Earlier Detection. Better Health.

[Lucence @LucenceHealth]

DNA looks for the breakpoint.
RNA reads the expressed fusion.

For gene fusions, that difference matters.

ctDNA remains essential, but ctRNA can reveal fusion signals DNA-only testing may miss.

Read more: https://t.co/WIV8gZHunH

[Lucence @LucenceHealth]

A patient smoked for years. Standard advice wasn't enough.

After learning about clonal hematopoiesis result, significant lifestyle changes were made.

Clonal hematopoiesis is linked to increased risks of heart disease, stroke, and leukemia.

Full video: https://t.co/LXdstSVoYA

[Lucence @LucenceHealth]

Cancer and CVD are often detected only after biological changes have progressed.

Advances in molecular testing expand how physicians study blood DNA/RNA, enabling earlier, more informed assessment.

In this video, CEO Dr Tan Min-Han shares impact across oncology, CVD and ageing.

[Lucence @LucenceHealth]

When cancer spreads to the brain, blood tests may not show the full picture.

Behind the blood-brain barrier, key signals can be missed by standard blood testing.

Cerebrospinal fluid analysis is opening a new molecular window into CNS cancers.

Read more: https://t.co/1BulZUAyP7

[Lucence @LucenceHealth]

In this inaugural piece from Lucence's new Clinical Insights series, we explore a growing challenge in cancer prevention: identifying cancers earlier where screening pathways do not exist, and the emerging role of liquid biopsy and MCED.

Full article: https://t.co/QfTUMw8kXG

[Lucence @LucenceHealth]

Dr. Gilberto Lopes, Chief of the Division of Medical Oncology at the University of Miami, explores how liquid biopsy — combining ctDNA and ctRNA analysis — supports personalized treatment planning.

Full video: https://t.co/UwuZPruyB5

[Lucence @LucenceHealth]

We're honored to collaborate with Mayo Clinic Laboratories to expand liquid biopsy access to more cancer patients.

[Mayo Clinic Labs @mayocliniclabs]

Mayo Clinic Laboratories and @LucenceHealth are collaborating to expand access to advanced cancer diagnostics. With the LiquidHALLMARK® liquid biopsy, we’re delivering actionable genomic insights to support precision medicine & drive better outcomes.
https://t.co/YfnK7mVE55

[Lucence @LucenceHealth]

We're pleased to announce that our LiquidHALLMARK assay has been granted Medicare coverage for all types of advanced solid tumors.

Grateful for this milestone that allows us to contribute to more patient care!

https://t.co/tHwVhoWlbp

[Lucence @LucenceHealth]

We were extremely honored to share our story with Singapore Prime Minister @leehsienloong during his #APEC2023 visit to the Bay Area.

It's been a 6-year journey to securing US Medicare coverage for our #liquidbiopsy tech to help US patients!

Photo credits: Enterprise Singapore

[Lucence @LucenceHealth]

Read 5 of our co-authored #ASCO23 abstracts here on multi-cancer early detection and ctDNA/ctRNA : https://t.co/VyWk1OwrSs

[gilberto lopes @GlopesMd]

Besides the regular @ASCO #ASCO23 program, there are a number of interesting sponsored presentations.
Join me for dinner & discussion about #ctRNA being a game changer for #lungcancer detection and treatment selection #liquidbiopsy.

June 3 - 6:30pm CT, hosted by @lucencehealth https://t.co/2akYOGXDTQ

@SylvesterCancer @ChristianRolfo @JackWestMD @n8pennell @NarjustFlorezMD @SamuelKareffMD @PriscilaBCMD @Latinamd @MudadRaja

[Lucence @LucenceHealth]

Our sincerest thanks to Singapore Deputy Prime Minister Heng Swee Keat for gracing the launch of LucenceINSIGHT™ at our US headquarters.

Press Release: https://t.co/eKX3MT6Kdu

#NoPatientLeftBehind

[Lucence @LucenceHealth]

We're pleased to announce that our LiquidHALLMARK assay has been granted Medicare coverage for lung cancer.

Deeply grateful for this opportunity to contribute to more patient care!

https://t.co/OZg4QNa8VD

[Lucence @LucenceHealth]

So glad to be presenting research at the 1st AACR Special Conference for Acute Myeloid Leukemia and Myelodysplastic Syndrome in Austin, Texas.

See you there!

[Min-Han Tan @minhantan]

@YawBediako_ Founder and CEO Yemaachi and among @NewAfricanMag's 100 Most Influential Africans, is on a mission to fix unequal healthcare for patients with African ancestry. Such a moment for this genomics partnership born out of our work together at @VAInstitute !

[Lucence @LucenceHealth]

Interested in how #mirrorbarcodes and #ctRNA can enable multi-cancer early detection?

We're committed to this mission and excited to share.

Our CEO @minhantan and CFO Vee Kiet Chan are looking forward to chat at #JPM2023!

[Lucence @LucenceHealth]

Year in Review

We're thankful to help patients across the United States, Asia and Africa.

And here's our deepest gratitude to all of you who make Lucence who we are.

Thank you to our partners, investors, healthcare providers and most of all, to our patients, for trusting us!

[Lucence @LucenceHealth]

Precision medicine test reports should be easy for physicians and patients to read.

So glad to share our new report format which offers comprehensive and accessible LiquidHALLMARK® results to empower oncologists.

Learn more using this video here! https://t.co/LuMXJE3XNK

[Lucence @LucenceHealth]

A wrap on ESMO Asia Congress 2022!

Thank you to @myESMO for organising a wonderful conference.

[Lucence @LucenceHealth]

See you at Booth E207 soon! #ESMOAsia22